Genmab — August 2025
-
Vi skal huske at 80% af al aktiehandel er algoitmestyret. Det skaber i høj grad kursmønstre i aktierne med volatilitet og uforudsigelighed, når store tradere på den korte og lange bane svinger med skiftende long og shortpostioner.
-
E L.. That's an aspect I completely agree with. It affects many Danish life sciences companies.
-
small new trial - Study of Epcoritamab as a Consolidation Therapy in CLL/SLL https://www.clinicaltrials.gov/study/NCT07108998
-
i am glad someone finally asked about the hexabody platform on the call. but the answer was a bit short, not convincing enough i think.
For the 'professionals' the article in Nature we recently saw on Hexabody-CD27 may be sufficient to instill confidence in the technology, but for the average investor like us that is not enough.
Bringing a new hexabody into the clinic before the end of the year is a big plus of course, but it will take time again,
to see if that works -
Jeg forstår ikke hvordan der skulle være mulighed for at der skulle kunne ske noget kursmanipulation? Uanset om det er rebotter eller mennesker der eksekverer handlerne - så vil en aktie vel ikke kunne holdes f.esk 20% under den den reelle værdi over en længere periode? Hvis nogen pludselig går short - så kan den måske holdes nede kortvarigt - men er jo heller ikke derfor med Genmab? Hvordan skulle der teknisk set kunne manipuleres?
-
Nej - men et eller andet sker der i strid med sund fornuft, og har gjort det længe ! Vi ved jo ikke om nogen har lagt en en længere sigtet plan sammen. Ikke fordi Bava skal blandes ind i Genmab, men her er der foregået noget som mange heller ikke forstår - vel over et års tid…..
-
På alle de fora jeg følger der omhandler specifikke aktier som "lige for tiden er alt for billige i forhold til potentialet" er det en folkesport at konspirationsteoretisere om banditter i habitter der på det snedigste holder aktierne nede med et eller andet diffust lusket formål for øje
-
there is of course a lot of pressure from investors to close the 'darzalex gap' and i understand they fully go for late stage assets for that reason, but for us it feels a bit like they forget about the early candidates as you say. i am pretty sure that is not true, but it certainly feels that way due to the news flow. we also hear nothing about hexelect anymore
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind